Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
Hemogenyx Pharmaceuticals (LSE:HEMO), a clinical stage biopharmaceutical company focused on blood and autoimmune disease treatments, has announced its total voting rights as of March 31, 2025. The company's total issued share capital consists of 4,093,539 ordinary shares of 1p each, with none held in treasury.
This figure serves as the denominator for shareholders calculating their notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The company operates through its US subsidiaries in New York City, where it maintains a state-of-the-art research facility developing several distinct product candidates and platform technologies.
Hemogenyx Pharmaceuticals (LSE:HEMO), un'azienda biofarmaceutica in fase clinica focalizzata sui trattamenti per malattie del sangue e autoimmuni, ha annunciato i suoi diritti di voto totali al 31 marzo 2025. Il capitale sociale totale emesso dall'azienda consiste in 4.093.539 azioni ordinarie di 1p ciascuna, senza azioni detenute in tesoreria.
Questo numero serve come denominatore per gli azionisti che calcolano i requisiti di notifica secondo le Linee Guida sulla Trasparenza e sulla Divulgazione della Financial Conduct Authority. L'azienda opera attraverso le sue filiali statunitensi a New York City, dove mantiene una struttura di ricerca all'avanguardia che sviluppa diversi candidati di prodotto distinti e tecnologie di piattaforma.
Hemogenyx Pharmaceuticals (LSE:HEMO), una compañía biofarmacéutica en etapa clínica centrada en tratamientos para enfermedades de la sangre y autoinmunes, ha anunciado sus derechos de voto totales a partir del 31 de marzo de 2025. El capital social total emitido por la compañía consiste en 4.093.539 acciones ordinarias de 1p cada una, sin acciones en tesorería.
Esta cifra sirve como denominador para que los accionistas calculen sus requisitos de notificación bajo las Reglas de Divulgación y Transparencia de la Financial Conduct Authority. La compañía opera a través de sus filiales en EE. UU. en la ciudad de Nueva York, donde mantiene una instalación de investigación de última generación que desarrolla varios candidatos de productos distintos y tecnologías de plataforma.
Hemogenyx Pharmaceuticals (LSE:HEMO)는 혈액 및 자가면역 질환 치료에 중점을 둔 임상 단계의 생명공학 회사로, 2025년 3월 31일 기준으로 총 의결권을 발표했습니다. 회사의 총 발행 주식 자본은 4,093,539 보통주로 구성되어 있으며, 자산으로 보유된 주식은 없습니다.
이 수치는 Financial Conduct Authority의 공시 지침 및 투명성 규칙에 따라 주주가 통지 요건을 계산하는 데 필요한 분모 역할을 합니다. 회사는 뉴욕시에 있는 미국 자회사를 통해 운영되며, 여러 독특한 제품 후보 및 플랫폼 기술을 개발하는 최첨단 연구 시설을 유지하고 있습니다.
Hemogenyx Pharmaceuticals (LSE:HEMO), une entreprise biopharmaceutique en phase clinique axée sur les traitements des maladies du sang et auto-immunes, a annoncé ses droits de vote totaux au 31 mars 2025. Le capital social total émis par l'entreprise se compose de 4.093.539 actions ordinaires de 1p chacune, sans actions détenues en trésorerie.
Ce chiffre sert de dénominateur pour les actionnaires calculant leurs exigences de notification selon les Règles de divulgation et de transparence de la Financial Conduct Authority. L'entreprise opère par le biais de ses filiales américaines à New York, où elle maintient une installation de recherche à la pointe de la technologie développant plusieurs candidats produits distincts et technologies de plateforme.
Hemogenyx Pharmaceuticals (LSE:HEMO), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Behandlung von Blut- und Autoimmunerkrankungen konzentriert, hat seine gesamten Stimmrechte zum 31. März 2025 bekannt gegeben. Das gesamte ausgegebene Aktienkapital des Unternehmens besteht aus 4.093.539 Stammaktien zu je 1p, ohne im Eigenbestand gehaltene Aktien.
Diese Zahl dient als Nenner für Aktionäre, die ihre Mitteilungspflichten gemäß den Offenlegungs- und Transparenzregeln der Financial Conduct Authority berechnen. Das Unternehmen operiert über seine US-Tochtergesellschaften in New York City, wo es eine hochmoderne Forschungseinrichtung unterhält, die mehrere unterschiedliche Produktkandidaten und Plattformtechnologien entwickelt.
- None.
- None.
LONDON, GB / ACCESS Newswire / March 31, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 March 2025 consists of 4,093,539 ordinary shares of 1p each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 4,093,539.
The figure of 4,093,539 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Hemogenyx Pharmaceuticals plc |
| |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
| |
Peter Redmond, Director |
| |
SP Angel Corporate Finance LLP |
| Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
Peterhouse Capital Limited |
| Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
What is the total number of voting rights for Hemogenyx Pharmaceuticals (HOPHF) as of March 2025?
How many shares of Hemogenyx Pharmaceuticals (HOPHF) are held in treasury?
What is the par value of Hemogenyx Pharmaceuticals (HOPHF) ordinary shares?
What type of treatments is Hemogenyx Pharmaceuticals (HOPHF) developing?
